Molecular Imaging and Innovative Therapies (IMOTION), EA7435, Bordeaux, 33000, France.
Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, Glasgow, G12 8TA, United Kingdom.
Sci Rep. 2018 Mar 16;8(1):4694. doi: 10.1038/s41598-018-22932-3.
RNA interference (RNAi)-based gene therapy has great potential in cancer and infectious disease treatment to correct abnormal up-regulation of gene expression. We show a new original method uses synthetic microRNAs combined with a thermo-inducible promoter to reduce specific gene expression. The targeted gene is the luciferase firefly reporter gene overexpressed in a subcutaneous tumor which allows the RNAi monitoring by bioluminescence imaging (BLI). The inducible inhibition was first demonstrated in vitro using genetically modified cells lines and then in vivo using the corresponding xenograft model in mice. Achieving spatio-temporal control, we demonstrate the feasibility to induce, in vivo, a specific gene inhibition on demand. Future applications of this RNAi-based gene therapy, which can be restricted to pathological tissue, would offer wide-ranging potential for disease treatment.
RNA 干扰(RNAi)为基础的基因治疗在癌症和传染病治疗方面具有很大的潜力,可以纠正基因表达的异常上调。我们展示了一种新的原始方法,该方法使用合成 microRNAs 结合热诱导启动子来降低特定基因的表达。靶向基因是在皮下肿瘤中过度表达的荧光素酶萤火虫报告基因,这允许通过生物发光成像(BLI)进行 RNAi 监测。首先在体外使用基因修饰细胞系进行了诱导抑制的证明,然后在体内使用相应的异种移植模型在小鼠中进行了证明。实现时空控制,我们证明了按需在体内诱导特定基因抑制的可行性。这种基于 RNAi 的基因治疗的未来应用可以局限于病理性组织,将为疾病治疗提供广泛的潜力。